VION Biosciences (Iron Path Capital) /
Prolytix
Iron Path Capital-backed VION Biosciences closed the acquisition of Prolytix from Edgewater Capital Partners on Sep 8.
The transaction, in context.
Terms were undisclosed. CEO Mark Thornton said the deal deepens VION in regulated large molecule bioanalytical and CMC services plus reagents, consumables, and diagnostic workflow inputs. [01]
Prolytix brings regulated bioanalytical and CMC services, research reagents, and custom sample collection products for biopharma and diagnostics customers. It is VION's sixth acquisition since 2023, building on the platform that already includes CTL and Ansh Labs. [01]
The people. The paper.
The stills posted with the deal, in post order. The @carrywatch post is the basis for this record.
Iron Path Capital-backed VION Biosciences closed the acquisition of Prolytix from Edgewater Capital Partners on Sep 8.
Supports the named parties, stage and people shown on this page.
Open the post on XWhere the record stands.
Closed, as posted
VION Biosciences (Iron Path Capital) acquired Prolytix from Edgewater Capital Partners (Closed, posted 13 Sep 2026).
Source 01
Follow the relationship.
The buyer, target and seller named in the post. Each connection returns to the same source.
Prolytix
The company the post describes as the subject of the deal.
Select an entity or relationship to see what the post says about it.
Mark Thornton
CEO